Skip to main content
. 2016 Aug 18;7(40):64615–64630. doi: 10.18632/oncotarget.11378

Figure 3. Co-evaluation of p53 and ATRX immunohistochemistry in 1p/19q non-codeleted oligodendroglial tumors.

Figure 3

52.6% (30/57) of 1p/19q non-codeleted oligodendroglial tumors lacking p53 positivity and loss of ATRX expression a. Photos of 1p/19q intact oligodendroglioma with negative p53 expression and positive ATRX staining b. -ve, negative; +ve, positive.